On Sept. 29, a three-judge panel on the District of Columbia’s appeals court decided that “through their product placement practices, Walmart and CVS mislead consumers into believing that homeopathic products are equivalent alternatives to FDA-approved over-the-counter drugs.”
The Center for Inquiry filed the two lawsuits citing the Consumer Protection Procedures Act in 2018 and 2019, but lower courts said CFI couldn’t bring suits on behalf of consumers because the nonprofit organization isn’t a consumer protection organization. The appeals court amended that statement to qualify CFI as a consumer protection organization.
“The Court of Appeals rightly recognized that giant retailers can’t just deny responsibility for how they present what are fundamentally worthless products,” Nick Little, CFI’s legal director, said in a news release.
CVS did not immediately respond to Becker’s requests for comment, but a Walmart spokesperson said the company disagrees with the decision.
“We are continuing to review the Court’s decision and are weighing our options for further appellate review,” Walmart spokesperson Abby Williams-Bailey said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
